OVERVIEW

IGF-1 LR3 (Receptor Grade) 1 mg is a laboratory-grade version of insulin-like growth factor-1 Long R3, a modified analog of the naturally occurring hormone IGF-1. The LR3 modification extends its half-life and reduces binding to IGF-binding proteins, allowing for greater receptor interaction and prolonged biological activity in research models. IGF-1 plays a central role in cellular growth, differentiation, and repair by activating the IGF-1 receptor and downstream signaling pathways such as PI3K/Akt and MAPK. Because of these mechanisms, IGF-1 LR3 has been widely studied in experimental settings for its potential effects on muscle cell proliferation, tissue regeneration, and metabolic regulation. The “receptor grade” designation typically refers to high purity intended for controlled laboratory use.

Due to its enhanced potency and extended activity compared to endogenous IGF-1, IGF-1 LR3 has been explored in research focused on anabolic signaling, recovery processes, and cellular growth dynamics. Its reduced affinity for binding proteins allows more of the compound to remain biologically active for longer periods, which may amplify its physiological effects in experimental environments. However, because IGF-1 signaling is closely linked to cell proliferation, careful evaluation of dosage and exposure duration is essential in research protocols. As with other growth factor analogs, IGF-1 LR3 is generally restricted to laboratory investigation and is not widely approved for general therapeutic use.